Skip to main content

Dr. Alireza Eghtedar, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
27
In the NPI registry since
2011
Medicare patients seen, 2024
217

Licensed in Texas since 2011, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2011Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    CO license 55429 (first issued 2015; active)
  • Emergency Medicine Physician
    TX license N9365 (first issued 2011; active)
  • Internal Medicine Physician
    CO license 55429 (first issued 2015; active) · MI license 4301099957

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
217
Services billed
35,298
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, daratumumab, 10 mg and hyaluronidase-fihj8,10026
Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg1,47021
Injection, magnesium sulfate, per 500 mg62428
Insertion of needle into vein for collection of blood sample42381
Injection, ondansetron hydrochloride, per 1 mg23214
Established patient office or other outpatient visit, 40-54 minutes16260
Infusion into a vein for therapy, prevention, or diagnosis, each additional hour15947
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less10959
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle8747
Administration of chemotherapy into vein, 1 hour or less6134

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Valacyclovir (valacyclovir hcl)
Other prescribers in Denver, CO
161
Acyclovir
Other prescribers in Denver, CO
100
Jakafi (ruxolitinib phosphate)84
Sirolimus48
Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim)
Other prescribers in Denver, CO
47
Lisinopril
Other prescribers in Denver, CO
35
Eliquis (apixaban)
Other prescribers in Denver, CO
31
Calquence (acalabrutinib maleate)29
Dexamethasone
Other prescribers in Denver, CO
28
Fluconazole
Other prescribers in Denver, CO
27

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 12 companies reported 27 payments worth $753 in total to this clinician.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Colorado →

Industry-funded research

Named as a principal investigator on 5 industry-funded studies in 2025, from 5 companies. The companies reported $177,400 in research payments for these studies, mostly to the institutions running them.

  • A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
    Sumitomo Pharma America, Inc. · Recruiting · NCT04988555
  • TAK-012-1501
    Takeda Pharmaceuticals U.S.A., Inc.
  • A Phase 1/2, Multicenter, Open-Label, Randomized Dose Ranging and Expansion Study of the Combination of Gilteritinib, Venetoclax and Azacitidine in Patients With Newly Diagnosed FLT3 Mutated Acute Myeloid Leukemia (AM…
    Astellas Pharma Global Development
  • A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide for Patients With Hematologic Malignancies
    National Marrow Donor Program
  • Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Denver

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 19, 2019), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1811280431. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.